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Or Alison Haywood 
Learning objectives 
After reading this article you shou ld be able to: 
• Describe the problems associated with the usc of 
ora l cytotox.ics not seen in traditional IV therapy. 
• Describe the advice to be given to patients 
regrading the safe handling of oral cytotoxics. 
• Describe the advice which should be given to 
pati ents and carers on the storage and disposal 
of ora l cytotoxics. 
Competencies addressed: 4.2.2, 4.2.3, 
4.3.3,5.3.1. 
Introduction 
It is well known that Australia's popu lation is ageing 
and that the incidence of cancer is highest in older age 
groups, so despite the fact that cancer i n~ i dence rates in 
Australia for both mell alld womell are projected to remain 
stable to 201 i.' the total number of new ~ases of ~ancer 
is projected to increase. To redu~e the resulting burden 
on the health care system it is imperati"e that patients 
be treated at home. The int rodu~tio n of several new oral 
cytotoxics, allowing the adm inistration 01 chemotherapeutic 
agents outside of traditional clinic settings, is making 
thi s goal atta inable.z While studies have shown that 
pat ients receiving chemotherapy preler the oral route of 
administration over the parentera l route, there are many new 
challenges in admin istering these agents in non-traditional 
environments.u Pharmacists. because of the ir accessibility, 
have an important ro le to play in counselling patients on 
the safe <lnd effective use of these cytotoxics, thus playing 
a pivotal role in the achievement of favourab le the rapeutic 
outcomes for these patients. 
Background and evidence 
The chang ing paradigm in cancer treatment associated with 
the introduction of nove l oral chemotherapeutic agents 
has shown many advantages, with greater convenience 
and flexibility in the location and schedu ling of medication 
adm inistration (Le. abil ity to undergo treatment at homel 
being the primary advantage. Other advantages of oral 
chemotherapy include the potentia l to reduce the use of 
health care resources for inpatient services, since patients 
are able to self-administer treatment. Furthermore, 
Pharmacist 
lltJe to self-administer trea/menl. 
problems with IV access and patients' fear of needles 
are eliminated when using the oral route. Thera peutica lly, 
oral admin istration of chemotherapy can provide more 
prolonged drug exposure compared with intermittent IV 
infusion, which may be important for drugs with schedu le-
dependent efficacy.3 
However, there are severa l potentia l problems associated 
with the use of oral chemotherapy flot seen in traditional 
IV therapy. Patients and careg ivers are required to assume 
greater responsibility for the patient ta king the proper 
dose, in the correct manner, at the appropriate time. 
This adm in istration of chemotherapy in a non-traditional 
environment may lead to an increased risk of dosing errors, 
side effects, drug interactions and flon-adherence.2-4 
Non-adherence may be as a result of confusion and 
misunderstanding about the treatment regimen, fa ilure to 
remember dosages or inappropriately 'catching-up' doses. 
Further, difficu lty or inability te swa llow so lid dosage 
forms and the subsequent safety issues which arise from 
this if patients or carers attempt to crush these ta blets 
before admin istration (e.g. elderly patients, chi ldren. 
patients suffering from nausea arid vomit ing, and pat ients 
receiving medicines via entera l feeding tubes), and the high 
cost oi the newer ora l chemotherapeutic agents provide 
add itional challenges in this area. Side effect profiles not 
associated with traditional chemotherapy have also been 
noted (e.g. rashes, hand-foot syndromeJ.3.5 highl ighting the 
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Tabl.e 1: Counselling notes for the provisi on of 
cytotox ic substances 
Indication of l15e A patient's knovvlcdge and understanding of 
their disease is an important faClOr affccting 
adherence to any drug therapy. 
Complexity and Many ora l cytoloxics have complex dosing 
duration of the regimens. Patients need 10 know how and when 
regiftlen to take their medication, for how long and 
what to do iA case of missed doses or vomiting 
after a dose. Patients should also be made 
aware of any expected tests during treatment 
le.g. blood tests!. 
Adverse effects Oml cytotoxics may each have unique adverse 
effect profil es; patients need to be aware 
of expected adverse effects, strategies for 
managing them (e.g. when to take anti emetics) 
and when to seek professional help, especially 
since patient monitoring is less freQuent with 
oral therapy. 
Drug, food and It is important that patients are aware of 
nutritional potential interar:lions and inform hea lth 
slIpplemenl/ professionals about all their current treatments, 
herhal medicine including those not prescribed by th eir doctor. 
interactions 
Storage and Medicines should be stored in an appropriate 
disposa l of place according to the manufacturer"s 
unused oral requirements, away from undue exposure 
cytotoxics to light, heat and humidity and away from 
children and pets. To avoid contaminating 
landfills and th e water supply, patients/carers 
shou ld not discard of unused oral cytotoxics 
in the household !rash Of flush them down the 
toilet. but bring them bacl:. to the pharmacy for 
proper disposal.~ 
importance of appropriate counsell ing that addresses the 
unique adverse effect profile associated with the individual 
agents. This PLlts the pharmacist in an important pos ition 
since they have the knowledge to provide guidance on the 
sale storage, dispensing. administration and disposal of oral 
cytotoxics as 'Nell as counsel patients to ensure the safe and 
effective use of their ora l chemotherapy. 
Safe and effective use of oral cytotoxics 
There are established policies and procedures in traditional 
chemotherapy for the safe handling of cyto10xics and other 
hazardous substances. e.g. Preparation of cytotoxic drug 
products in the PSA Professional Practice Srandords' and 
the SHPA Standards of prBCtice for the provision of Oral 
chemotherapy for the treatment of canC8r,l and for the 
safe handling of CYlOtoxic drugs in pharmacy departments.s 
These are for the protect ion of hea lth Cilre personne l and 
Ac\:redited by the CPO&PI Program ./ 
patients from harmful exposure to hazardous substances 
and also for the protection of the workplace and environment 
from contamination. HOivc"cr, there are limited guidelines 
specific to safe handl ing of oral cytoloxics in the home or 
other non-traditiona l settings .' Further. little information 
is available to pharmacists on effective means of managing 
non-adherence to ensure positive "therapeutic outcomes. 
The foll owing information will provide valuable insight into 
the safe and effer:tive use of ora l cytotoxics. 
Pati enl/carer education 
Patient and/or carer counselling is the most critical step 
in ensuring effective therapeutic outcomes. since patients 
will be self administering treatmen t and will therefore not 
have ready access to traditionill sources of specialised 
informiltion provided at the inpatient setting by heill th 
care professionals.'-' Se lf administration at home or other 
non-traditional sel1ings may increase the risk of medication 
errols. compromise therapeutic efficacy and patient safety. 
and lead to inadvertent exposure of family members 
to hazardous substances and contamination of landfills 
and the water supply. ' Funner, many ora l cytotoxics have 
a narrow therapeutic index ilnd comple)( dosing regimens, 
and patients may pe rceive oral drug the rapies as being 
less dangerous than parenteral therapies.1lmportant 
patient counselling notes are listed in Table 1. J,5-1 
Special administration requirements 
and safe handling 
Patients should handle their medication themselves, if at aU 
possible. If a family member/carer needs to assist the patient 
they should wash their hands before and after they handle 
the medication and shou ld wear nitrile gloves.4 The fo l lowing 
guidelines are given for modifying solid dosage forms fOI 
patients unable 10 swallow a tablet or capsule: 1u 
Meking 8 teb/et dose into a mixture 
1 You will need: Ii) A pair of gloves; Oil an oral syringe and 
(iii) a plastic measuring cup or glass. 
2 Put on the gloves. 
3 Place the required number or tablets or part of a tablet 
into the measuring cup or glass. 
4 Pour a little water on the lablets and allow to disperse. 
This may take a lew minutes. Do not try 10 make the 
tablel disperse fasler by stirring or shaking the container. 
Alternstive method: Place the required number of tablets 
or part of tablet into a tablet crusher; gently add some 
water mal:.i ng sure the powder is washed off the crusher. 
5 Draw up the dose into an oral syringe and give the dose 
to your patient. 
6 Wash the gloves. oral syringe and measuring cup/glass in 
warm, soapy water. These can be used again for further 
doses but do not use them for any other purpose . 
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Making a c8psule dose into a mixture 
1 You will need: {il A pair of gloves; (i i) a mask; (iii) an oral 
syringe and livj <l plastic measuring cup or glass. 
Z Put on the gloves and mask. 
3 Put a Il tlle water into the glass. 
4 Empty the contents of the capsule onto the water. 
5 Draw up the dose into an oral syringa and give the dose 
(0 your patient. 
6 Wash the gloves. ora l syringe and measuring cup/glass in 
warm, soapy waler. These can be used again for further 
doses but do not use them for any other purposo. 
7 Wrap the empty plastic capsule shell in paper and throw 
it away with the mask as described below. A new mask 
should be used for each dose. 
What to do in C8se of a spill 
• If contaci o~curs with your skin, you must wash the area 
immed iately. using plenty of wa ter. If the s!<.in is sore you 
should contaci your GP for advice. 
• If contact occurs with your eyes, wash immediately 
with plenty of water for at least 10 minutes. If after 
this your eyes are sore you should go to your nearest 
emergency department. 
• If you spill any cytOtoxic medicines on the work 
surface or floor. wearing glovos, covsr the spillage 
with kitchen paper. Wipe the area wi th wate r then 
clean with household cleaner and water. Used 
kitchen paper and other items used to clean up the 
spillage shou ld be double bagged and disposed 
of wi th the hou sehold wlIste. If any cytotoxic 
medicine is spi lt on clothing, the spill shou ld be 
blotted dry with kitchen paper. Clothing should be 
removed immediately and washed separately from 
other iterns 
• Waste products. such as used paper towels. vomit 
and dirty disposable nappies, should be placed in 
a double-lined plastic rubbish bag. The double bag 
shouid be disposed of as for normal household waste. 
Oral cytotoxics and enteral feeding tubes 
Crushing lablets to administer them via an enteral feeding 
tube not only inc/eases the incidence of tube occlusion but 
also increases the risk of adverse effects. Wherever possible. 
health care professionals should consider an alterna live 
formulation of the same drug or a different drug that has lha 
same therapeutic effect. Occupational exposure would also 
need to be considered - contact with the skin and inhalation 
of dust should be avoided and protectivl! equipment/devices 
should be used. such as closed-system crushing syringes." 
Detailed guidelines. including drug monographs, are given 
in texts such as the Handbook of Drug Administration Ilia 
Enteral Feeding Tubes. II 
.'Li -:.::67.::.-6 ) Pharmacist 
Adherence and memory aids 
Patient non-adherence is an issue that oncology clin icians 
struggle wi th in various practice settings . Suggestions for 
improving pati ent adherence include:'·! 
• There is strong advocacy tor the use of dia ries to monitor 
patient adherence. sillCe this method has been s~own 
to be fairly effective, i.e. asking patients to maintain a 
diary of doses taken and then present the diary at the 
time of drug renewal to veri fy that doses were taken as 
prescribad. The times of administration and whether the 
dose was taken with food can also be retorded. 
• Patients can also be asked to bring their medication 
containers with them so that pill counts can be performed 
to ascertein whether the correct number 01 doses was 
taken as pres~ribed. 
• Patients wi th complex medication schedules can be 
provided with a customised calendar listing each 
prescribed dose. Patients can than be asked to place a 
checkman: on the ca lendar alter taking each dose, and to 
bring the calender to every visit. 
Advice for safe dispensing to prevent 
medication errors and inadvertent 
exposure of health care providers, 
patients, and caregivers to hazardous 
drugs has been incorporated into 
the prescribing information for many 
oral cytotoxics. 9 
• New electronic methods allowing health care providers 
to monitor patient adherence are being explored, whele 
the prescriber, patient and laboratory are wireless!y 
linked enab ling the prescriber to comm unicate patient 
instructions for dosage modification Daserl on laboratOry 
test results. 
Generally. cytotoxic preparat ions or other medicines posing 
occupational health and sa fety risks are general ly unsuitable 
for packaging into Dose Administration Aids, however the 
risk-benefi t of packing must be considered; for example. 
packing may be appropriate where non·compliance is 
considered to be a greater risk. 12 
Pharmacist education 
Advice for safe dispensing to provent medication errors and 
inadvertent exposure 01 health care providers. pat ients, 
and caregivers to h,)Zardous drugs has been incorporated 
into the prescribing information for many oral cytotO)(;cs. ~ 
Information about the proper use of the medication is often 
./ 
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~~~~;:;:': brina thair modicatfon r;onlainers with 
rhem so rhar pill COIJ(l/S can be p6lfcxmed fO ascertain w/JOthcr Ihe 
correct number of doses was taken us prescribed. 
available from many mallufa~tlJfers for use as handouts and 
in the eMls. Pharmacy owners may consider developing 
a counselling program for their community pract ice or 
delegat ing spe~ ial i sed pat ient education to a specific 
hea lthcare team member w ithin their practice. 4 Pharmacists 
should be encou raged to engage in re levant ePE act ivit ies 
to remain abreast of new chemotherapeutic treatments. 
Questions 
1. Problems associated with the use of oral cytotoxics in 
patients not seen in the tradi tional IV regimens include: 
a) Patients and caregivers assumir,g less responsibi lity in the 
administration of a correct dose. 
b) A decreased risk of side effects, drug interactions aOO lock of 
patient cOOlp li<lnce. 
c) Inability of elderly populations to swallow tablets and safety 
concerns regard ing crushing of cytotoxics. 
0) l ow cost of oral chemotherapeutic agents. 
el c and d. 
2. The fo llowing represents advice given by the pharmaCist, 
which patients should adhere to in respect of the 
administration of their oral cytotoxics: 
a) If at all ~J3Si blc do not lJ8ndle the medk~ti~n yoursell. 
b) II a family member assists in administering your medication, they 
should wash their hflnds prior to and after handling the medication. 
~) It is not nuccssary for the person assistirlg in the administration of 
the oral cytotoxics to wear gloves, 
dl B. b a~d c. 
91 b ar.d c. 
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By understand ing the mechan ism of action and metabolic 
pathways of the newer ora l agents, pharmacists wi ll be ab le 
to predict and take s!eps to avoid Ltnwanted drug interactions 
and 10xicitylJ and arc thus fulf ill ing an important role in 
ensLtring the provision of optima l pharmaceutical care and 
drug therapy for people with cancer. 
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3. If during the marlipulation of arl oral cytotoxic (e.g. crushing 
of tablets or emptying of capsu le contents) an accidental 
spillage occurs, the following practices should be followed: 
al There is 1\0 need to wash any area of skin that has come into direct 
comact with the cytotoxic, but contact \'!lur G? 
bl If contact occurs with the eye. WJS~ immediJtcly with water. 
cl If ~ ~y spillage oc~urs on dothing. there is ~ o need to wash tilese 
items separate ly. 
dl Any waste products such as paper towels used in the spillage 
sho~ l d be placed in a double-lined pl ~stic rubbish bag. 
el b aOO d. 
4. Pharmacist advice on correct storage and disposal of oral 
cytotoxics should include the fo II0\'Vin9: 
al Ora l cytoto~ic medicines should be Slored away from heat and 
humidity. 
bl Unused ora! cytotoxics may be disposed 01 in the household tresh, 
but not flushed down the toilet. 
c) Pa tients shoold always retltfrl unused cytotoxics to the pharmacy for 
appropriate disposal. 
dl a. b and c. 
el a and c. 
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